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Abstract
Objective: To determine whether 3% w/w levomenthol added to ibuprofen gel (5% w/w)
improves its efficacy compared with ibuprofen gel alone or diclofenac gel (1.16%) for the treat-
ment of soft-tissue injuries.
Methods: A total of 182 patients with acute soft-tissue injuries participated in a randomised,
single-blind, single-dose study to assess the efficacy and safety of three topical analgesic gels.
Efficacy was assessed as the score change in a numeric rating scale for pain.
Results: The median time to significant pain relief was 20 minutes for the ibuprofen/levomenthol
and diclofenac gels but 25 minutes for ibuprofen gel. At 2 hours, significantly more
patients treated with ibuprofen/levomenthol gel reported a cooling sensation (45.8%)
compared with diclofenac (16.4%) or ibuprofen (14.7%) gels, and both ibuprofen/levomenthol
and diclofenac gels provided significantly more effective global pain relief compared with ibupro-
fen gel. Few adverse events and no serious adverse events related to study medication
were recorded.
Conclusions: Although all gels effectively relieved pain, both ibuprofen/levomenthol and diclo-
fenac gels provided superior global pain relief compared with ibuprofen gel, with a shorter
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Introduction
Non-steroidal anti-inflammatory drugs
(NSAIDs) administered orally or intrave-
nously typically reach relatively high con-
centrations in the blood to achieve
effective tissue concentrations at the site of
pain and inflammation. However, these
high concentrations can be associated with
adverse effects such as dyspepsia and gas-
trointestinal bleeding. In contrast, topical
NSAIDs are applied directly to the painful
area, making them less likely to accumulate
at physiologically active concentrations
elsewhere in the body. The precise formula-
tion of a topical medication may influence
the speed of drug absorption. In fact,
because formulation chemistry can signifi-
cantly affect the rate and quantity of drug
distribution to subcutaneous injured tis-
sues, the effect of formulation may be as
important as the individual NSAID used.
Rapid absorption formulations are
enhanced by substances that improve skin
penetration, and gel formulations are par-
ticularly suitable for this purpose.1 Gels
containing the NSAIDs diclofenac, ibupro-
fen, and ketoprofen are particularly effec-
tive in providing pain relief for acute
musculoskeletal conditions.1 Topical men-
thol, which stimulates thermoreceptors,
has also been used to enhance the efficacy
of analgesic gels containing NSAIDs.2 The
focus of the present study was to assess the
effect of adding levomenthol, a form of top-
ical menthol, to an ibuprofen gel.
Ibuprofen is a non-opioid analgesic and
NSAID which reduces pain, stiffness, and
inflammation.1 It is used to treat the symp-
toms of osteoarthritis, rheumatoid arthritis,
and gout. Ibuprofen is a cyclooxygenase
(COX) inhibitor and its analgesic and
anti-inflammatory properties are particu-
larly effective in treating soft-tissue injuries
when topically applied. A recent review of
topical NSAIDs noted that ibuprofen gel
demonstrated high clinical efficacy in the
treatment of acute musculoskeletal pain in
adults, with a number-needed-to-treat
(NNT) value of 3.9 (95% confidence inter-
val [CI], 2.7–6.7) from two studies with out-
comes of marked improvement or complete
remission.1 Ibuprofen has fewer side-effects
and a lower risk of gastrointestinal bleeding
and ulceration than many other NSAIDs.3
A major advantage of applying NSAIDs
directly to the affected area in gel form is
that targeted pain relief can be achieved
without systemic side-effects.1,4
Diclofenac, another NSAID, exerts an
anti-inflammatory effect and can be admin-
istered regularly over an extended period to
relieve pain and stiffness associated with
rheumatoid arthritis and advanced osteoar-
thritis.3 Diclofenac is effective in treating
various types of acute and chronic pain
and inflammatory conditions. As with all
NSAIDs, diclofenac inhibits prostaglandin
synthesis by inhibiting COX-1 and COX-2.
However, recent research has demonstrated
that the pharmacological activity of diclo-
fenac extends beyond COX inhibition.
2 Journal of International Medical Research 0(0)
Diclofenac may inhibit the thromboxane-
prostanoid receptor, affect arachidonic
acid release and uptake, inhibit lipoxyge-
nase enzymes, and activate the nitric
oxide-cGMP antinociceptive pathway.5
The EmulgelVR formulation of diclofenac
has a very high clinical efficacy in treating
acute musculoskeletal pain in adults, with
an NNT value of only 1.8 (95% CI,
1.5–2.1) as demonstrated in two studies
using at least 50% pain intensity reduction
as the outcome measurement.1
Menthol is an alcohol from mint oils
used as an inhalation and topical antiprur-
itic.3 It can exist in two enantiomeric forms
(þ/–), occurring as levomenthol (–) or race-
mic menthol ().6 Levomenthol is the most
abundant optical isomer and is the form
used in menthol gel products. Menthol
reportedly acts as a ‘cooling-mimetic’
agent, producing the sensation of cooling
without reducing skin temperature.7,8
Following topical application, menthol
stimulates thermoreceptors to generate
cold or warm sensations, and has an anaes-
thetic effect.2,9,10 Menthol can also enhance
the skin penetration of topical analgesics
and may increase their effectiveness in
relieving pain.2 In addition, many topical
analgesic treatments are formulated in an
aqueous/alcoholic gel, and this preparation
has a soothing and rapid cooling effect
when applied to the skin.11
The aim of this study was to investigate
whether adding levomenthol to an ibupro-
fen gel reduced the time taken for a signif-
icant analgesic effect to occur in patients
with soft-tissue injuries. We applied differ-
ent gels and collected self-reported pain
relief data over a 2-hour assessment period.
We also measured other parameters (includ-
ing cold/warm sensations) that might be
linked to analgesia to determine whether
the addition of levomenthol enhanced the
performance of ibuprofen gel. Comparisons
were also made with a gel containing
diclofenac, generally considered the most
effective topical NSAID.1,12
Patients and methods
Study design
This was a single-centre, randomised,
single-blind, parallel-group, single-dose
study of the efficacy of ibuprofen gel (5%
w/w) containing 3% w/w levomenthol (ibu-
profen/levomenthol gel) for the treatment
of strains, sprains, and sports injuries. The
efficacy of this gel was compared with that
of ibuprofen gel (5% w/w) without levo-
menthol and with a gel containing diclofe-
nac (1.16%).
Study measures
The primary objective of the study was to
determine the time to significant pain relief
for patients with soft-tissue injuries who
were treated using ibuprofen gel, ibupro-
fen/levomenthol gel, or diclofenac gel.
Significant pain relief, the primary endpoint
for our study, was defined as a reduction of
2 points on an 11-point numeric rating scale
(NRS) for pain.13,14 Study participants also
provided information at specific time points
regarding any cooling/warming sensations
they experienced, and evaluated the gels
for analgesic efficacy (11-point NRS) and
level of global pain relief (7-point NRS) at
2 hours after gel application.
Sample size calculation
The sample size calculation was performed
using Minitab statistical software (ver. 17;
Minitab Ltd., State College, PA, USA)
based on a three-group, one-way analysis
of variance. Assuming a standard deviation
for time to pain relief of 8 minutes, a sample
size of 51 was required for each group
to detect a between-group difference of
5 minutes at 80% power and 5% signifi-
cance level. To allow for non-parametric
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testing, we applied a rule of thumb that
recommended increasing the parametric
sample size estimate by 15%.15 The
sample size for this study was therefore 60
patients per group.
Recruitment
All study participants had experienced an
acute soft-tissue injury and were recruited
via referral from local pharmacies and
healthcare professionals or by responding
to study advertisement. Potential partici-
pants were screened to determine whether
they were suitable for the study using
specific inclusion and exclusion criteria.
Suitable participants attended a clinic
appointment and were shown how to com-
plete the assessments on an electronic
device. Patients were unaware that a pain
assessment of 6 or greater on an 11-point
NRS for pain was required to enter the
study. Patients who met this requirement
and all other inclusion/exclusion criteria
were randomised 1:1:1 to one of the three
treatments. The study was approved by the
East of Scotland Research Ethics Service
(EoSRES) REC2 (16\ES\0009), and was
conducted in accordance with the principles
of the Declaration of Helsinki. All patients
provided written informed consent prior to
undergoing any study procedures.
Inclusion and exclusion criteria
Male and female patients between the ages
of 16 and 75 years (inclusive) were eligible
for participation. Patients with an acute
soft-tissue injury who reported being in at
least moderate pain at baseline (6 on an
11-point NRS for pain) were enrolled in the
study, unless any of the following exclusion
criteria were applicable: inflamed or broken
skin in the area to be treated; allergy to
aspirin, NSAIDs, or any of the gels’ ingre-
dients; chronic injury, active peptic ulcer,
or significant renal disease; pregnancy or
lactation; use of an analgesic treatment
within the preceding 8 hours or a slow-
release/long-lasting analgesic treatment
within the preceding 24 hours; history of
severe hepatic impairment or alcohol
abuse; participation in a clinical trial
within the preceding 30 days.
Study procedures
Eligible patients who met the inclusion and
exclusion criteria were randomised to
receive one of the three gel treatments
using a computer-produced randomisation
schedule where each eligible patient was
allocated the next available unique patient
number. Following baseline assessments
and instructions on how to record pain
levels using a standard tablet, patients had
gel applied by a healthcare professional in
accordance with product instructions. The
patient was then supervised by another
member of the research team during the
2-hour assessment period. Therefore, both
the patients and the investigators supervis-
ing the assessments were blinded to the ran-
domisation schedule. The assessment rooms
were “mentholised” to mask the distinctive
odour of levomenthol. Drug supplies were
prepared and labelled according to Good
Clinical Practice. Patient data were collect-
ed using a customised tablet program,
stored on an internal database within the
application, and subsequently uploaded to
a local database server. Patients were
prompted electronically to ensure accurate
completion of each assessment. The
member of staff supervising the assessments
also prompted patients to record their pain
levels at each of the time points.
Data collection
Patients completed 11-point NRS (pain)
and 11-point warming/cooling scale
(WCS) evaluations at 17 time points
(1, 2.5, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 40,
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50, 60, 75, 90, 105, and 120 minutes). In
addition, a global assessment of pain relief
was made on a 7-point scale (‘no relief’
to ‘complete relief’) at the end of the
2-hour period.
Adverse events
Patients were asked whether they had any
untoward symptoms other than their injury
prior to gel application and at the end of the
2-hour assessment period. In addition,
patients were followed up by telephone 1
to 3 days after the assessment and asked
to provide details of any adverse or serious
adverse events they had experienced in the
intervening period. Each event was
recorded and its likely relationship to
study medication was determined by a med-
ically qualified trial investigator.
Statistical analysis
Primary outcome. The primary outcome for
this study was the time to significant pain
relief, defined as a two-point decrease in
pain score from baseline and analysed at
30 and 120 minutes after gel application
using survival analysis (log-rank test) per-
formed at a 5% significance level. The sur-
vival analysis method was used because
some study participants may not experience
significant pain relief at the end of the
2-hour assessment period.
Secondary outcomes. Analgesic efficacy at
2 hours, defined as the median difference
in pain score between baseline and
2 hours, was analysed using a Kruskal–
Wallis test performed at a 5% significance
level. To assess whether there was an asso-
ciation between treatment group and expe-
rience of cooling at 2 hours following
application, herein referred to as cooling
effect, a Pearson chi-squared test was per-
formed at the 5% significance level.
Differences in global pain relief at 2 hours
and the level of pain relief experienced at
this time point were compared between
the different treatments using a Kruskal–
Wallis test performed at a 5% significance
level. All primary and secondary analyses
were performed using Minitab statistical
software (ver. 17; Minitab Ltd.).
Results
Demographic and injury data
Age and gender data for the study popula-
tion are shown in Table 1. Of the 182 par-
ticipants recruited to the study, 109 (59.9%)
were male and 73 (40.1%) were female. The
mean age of study participants was 36.18
years (range: 17–67 years) and was similar
for males (36.65 years) and females
(35.47 years).
Table 2 summarises the injuries reported
by the study participants. Of the 182 indi-
viduals who took part in the study, 137
(75.27%) reported having an injury dura-
tion of more than 1 week, 27 (14.84%)
reported a duration of 4 to 7 days, and 18
(9.89%) reported a duration of 1 to 3 days.
The most common injury site was a lower
limb (79 participants). Sprains and strains
were the most common type of injury,
reported by 129 study participants
(70.88%). Muscular aches were reported
by 42 study participants (23.08%), whereas
11 individuals (6.04%) reported bruising or
soft tissue injuries. A total of 104 (57.14%)
study participants were affected by sporting
injuries. Injury types and durations were
Table 1. Age distribution (years) of the 182 study
participants.
Mean age
(years)
Standard
deviation Range
Study (n¼ 182) 36.18 12.09 17–67
Men (n¼ 109,
59.9%)
36.65 13.17 17–67
Women (n¼ 73,
40.1%)
35.47 10.32 18–57
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similar among the three randomised gel
treatment groups. There were fewer neck
injuries in the diclofenac (1) than in the ibu-
profen (6) or ibuprofen/levomenthol (7)
gel treatment groups. However, there were
only 14 neck injuries in total, so this was
unlikely to have had a significant effect on
the results.
Study participation
Of the 182 study participants, 181 com-
pleted the 2-hour assessment. One partic-
ipant was unable to provide responses on
the tablet because of an error in the data
collection system; this patient’s data were
not collected manually or analysed. Of the
181 participants who completed the
assessment, 59 had been randomised into
the ibuprofen/levomenthol gel treatment
group and 61 each had been randomised
into the diclofenac and the ibuprofen gel
groups. The patient who failed to complete
the assessment period had been randomised
to the ibuprofen/levomenthol gel group. In
total, some time-point data were missing
from 13 patients, but this constituted only
0.6% of all pain data. Of the 182 partici-
pants, 180 completed the telephone follow-
up. Two participants (both from the ibupro-
fen treatment group) failed to complete the
telephone follow-up.
Time to pain relief
Application of ibuprofen/levomenthol gel
or diclofenac gel resulted in a shorter
median time to significant pain relief
(20 minutes) compared with application of
the ibuprofen gel (25 minutes). Additional
survival analyses were performed to allow
the inclusion of data from patients who
failed to reach the primary endpoint
defined as significant pain relief (a two-
point drop in pain score from baseline).
These survival analyses, shown in Figure
1, did not result in statistically significant
differences among the three treatment
groups at 30 minutes or 120 minutes.
However, at the 30-minute time point,
71.2% of patients in the ibuprofen/levo-
menthol gel group reported a 2-point
reduction in pain score compared with
only 55.7% of patients in the ibuprofen
gel group (Figure 2). We calculated that
a study population of approximately 160
patients per group might have shown a
statistically significant difference between
the ibuprofen/levomenthol gel and ibupro-
fen gel treatments at 30 minutes.
Although a statistically significant differ-
ence was not demonstrated, Figure 2
shows that throughout the 2-hour assess-
ment period, more patients who used
ibuprofen/levomenthol gel or diclofenac
gel tended to report significant pain
relief compared with patients who used
ibuprofen gel.
Table 2. Injuries reported by study participants.
Number
(N¼ 182)
% of
total
Duration of injury (days)
<1 0 0.00
1–3 18 9.89
4–7 27 14.84
>7 137 75.27
Site of injury
Neck 14 7.69
Shoulder 29 15.94
Upper limb 15 8.24
Back 45 24.73
Torso 0 0.00
Lower limb 79 43.41
Type of injury
Sprain/strain 129 70.88
Muscular ache 42 23.08
Bruising/soft tissue 11 6.04
Sporting injury
Yes 104 57.14
No 78 42.86
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Figure 1. Survival analysis showing the proportion of patients yet to report significant pain relief (2-point
reduction in pain score from baseline) at successive time points.
Figure 2. Proportion of patients achieving significant pain relief at each time point.
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Analgesic efficacy at 2 hours
We also determined analgesic efficacy 2
hours after gel application (Table 3). For
each treatment group, we calculated the
median change in pain score (11-point NRS
for pain) between baseline and the 2-hour
time point. The median score change was
–3 for the ibuprofen/levomenthol and diclo-
fenac gels and –2 for the ibuprofen gel. Tests
for differences among the three groups failed
to reach the level of statistical significance
(p¼ 0.070). The mean changes shown in
Table 3 are descriptive only.
Cooling effect
At 2 hours after gel application, significantly
more patients in the ibuprofen/levomenthol
gel treatment group reported cooling
(45.8%) compared with the diclofenac
(16.4%) and ibuprofen (14.7%) groups
(p< 0.001). The differences in cooling data
collected over 17 time points during the
2-hour assessment period are shown in
Figure 3. This result indicates that only the
ibuprofen/levomenthol gel provided pro-
longed cooling, attributable to the presence
of levomenthol. Note that the study design
Table 3. Median changes in pain scores between baseline and 2 h.
Total
patients (n)
Mean
baseline
score
Mean
score
at 2 h
Median
change IQR
Mean
change
Ibuprofen/levomenthol 59 7.2 4.0 3.0 (5.0, 2.0) 3.373
Diclofenac 61 7.2 4.4 3.0 (4.0, 1.0) 2.705
Ibuprofen 61 7.2 4.5 2.0 (4.0, 1.0) 2.705
IQR: inter-quartile range.
Figure 3. Association of ibuprofen/levomenthol gel with prolonged cooling.
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prevented patients reporting cooling at a
particular time point if they had already
reported warming at the same time point.
Global pain relief at 2 hours
All 181 participants who completed the
2-hour assessment period were asked to
rate the level of global pain relief they had
experienced. NNT values were also calcu-
lated based on the number of patients
who experienced moderate pain relief or
better. The results are shown in Table 4.
The global pain relief data were coded to
a 7-point scale and a statistically significant
difference was found in the median global
pain values among the three groups
(Kruskal–Wallis test, p¼ 0.006). There
was no significant difference in median
global pain relief between the ibuprofen/
levomenthol gel and diclofenac gel groups,
but treatment with either of these gels
resulted in a superior outcome compared
with treatment with ibuprofen gel that was
equivalent to 1 point on the scale. This
result, as shown in Figure 4, indicates that
the median result of treatment with ibupro-
fen gel is ‘mild relief,’ whereas the median
result of treatment with ibuprofen/levomen-
thol gel or diclofenac gel is ‘moderate
relief.’ This statistically significant 1-point
difference was observed on the 7-point
scale and not on the 11-point NRS used
in the other analyses.
Adverse events
No adverse events were recorded during the
in-clinic assessment period. Subsequent
adverse events recorded at follow-up are
listed in Table 5. In total, seven adverse
events were recorded, five of which were
categorised as unrelated to study medica-
tion. One adverse event, where the patient
reported a warming sensation on the neck,
was judged ‘unlikely’ to be related to the
study. The remaining adverse event, where
the patient reported ‘red itchy skin where
gel applied’, was judged as ‘definitely’ relat-
ed to the study medication. Both of these
patients were from the diclofenac treatment
group. A single serious adverse event was
recorded (Table 6), in which the patient
required surgery to pin a fractured fibula.
This serious adverse event was evaluated as
unrelated to study medication.
Discussion
The purpose of this study was to assess the
effect of adding levomenthol to ibuprofen
gel. Diclofenac gel was included as a relevant
comparator. The study assessed the efficacy
and safety of these three topical analgesic
Table 4. Number of patients in each treatment group reporting each level of global pain relief at 2 h.
Ibuprofen/levomenthol
gel (n¼ 59)
Diclofenac
gel (n¼ 61)
Ibuprofen
gel (n¼ 61)
No relief 1 (1.7%) 4 (6.6%) 5 (8.2%)
Slight relief 10 (16.9%) 10 (16.4%) 14 (23.0%)
Mild relief 15 (25.4%) 13 (21.3%) 14 (23.0%)
Moderate relief 6 (10.2%) 21 (34.4%) 14 (23.0%)
Considerable relief 18 (30.5%) 10 (16.4%) 9 (14.8%)
Almost complete relief 7 (11.9%) 2 (3.3%) 4 (6.6%)
Complete relief 2 (3.4%) 1 (1.6%) 1 (1.6%)
NNT (moderate relief) 1.79 (95% CI,
1.45–2.36)
1.79 (95% CI,
1.46–2.36)
2.18 (95% CI,
1.69–3.02)
NNT: number needed to treat; CI: confidence interval.
Wade et al. 9
gels for the treatment of soft-tissue injuries.
We found that all three gels provided effec-
tive pain relief. No serious adverse events
related to study medication were reported,
and only one adverse event of mild severity
was considered related to study medication
(diclofenac). Although the time to pain relief
results did not demonstrate statistically sig-
nificant differences, the ibuprofen/levomen-
thol gel and diclofenac gel had shorter
median times to significant pain relief than
the ibuprofen gel. Of the three gels, only the
Table 5. Adverse events.
Treatment Age Sex
No. of
events Event Severity
Related to
study
Diclofenac 59 M 1 Warming sensation on neck Mild Unlikely
Diclofenac 31 M 1 Red itchy skin where gel applied Mild Definitely
Ibuprofen/
levomenthol gel
42 F 1 Swelling to feet and ankles Mild None
Ibuprofen 43 M 2 1: Feeling high temperature
2: Night sweats
Mild
Mild
None
None
Diclofenac 18 M 2 1: Pressure at base of back
2: Pressure on forehead
Mild
Mild
None
None
F, female; M, male.
Table 6. Serious adverse event.
Treatment Age Sex
No. of
events Event Severity
Related to
study
Diclofenac 48 M 1 Operation to pin
fractured fibula
Moderate None
M, male.
Figure 4. Between-group comparison of global pain relief at 2 hours.
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ibuprofen/levomenthol gel provided pro-
longed cooling for up to 2 hours after gel
application. In addition, there was a statisti-
cally significant difference in median global
pain relief among the three treatment groups
2 hours after gel application; no difference
was observed between the ibuprofen/levo-
menthol gel and the diclofenac gel, but treat-
ment with either of these gels resulted in a
superior outcome compared with ibuprofen
gel treatment. This finding indicates that the
addition of levomenthol to ibuprofen gel not
only produces a potentially beneficial cool-
ing effect but might also enhance its analge-
sic efficacy.
NRSs were selected as appropriate for the
quantification of pain relief in our study
based on a systematic literature review that
included 54 studies assessing pain intensity
in adults with postoperative pain, cancer,
and other conditions. The authors consid-
ered compliance rates, responsiveness, ease
of use, and applicability of different pain
scales and found that an NRS was applica-
ble for unidimensional assessment of pain
intensity in most settings.16
The primary endpoint for our study was
the time to onset of significant pain relief,
which was defined as a reduction of two
points on an 11-point NRS for pain.
However, not all patients achieved this
level of pain relief by the end of the 2-hour
assessment period. The UK Medicines and
Healthcare products Regulatory Agency has
stated that “It is unlikely that a time to onset
of relief of more than 30 minutes would be
considered to be ‘fast’ for a product for relief
of an acute condition.”17 Consequently, the
median time to significant pain relief was
reported for each gel. For both the ibupro-
fen/levomenthol and the diclofenac gels, this
was shorter (20.0 minutes) than that for the
ibuprofen gel (25.0 minutes), indicating that
the ibuprofen/levomenthol gel and the diclo-
fenac gel were faster acting. However, the
median time to significant pain relief was
less than 30 minutes for all three gels.
Regardless of aetiology, pain is a subjec-
tive experience communicated only through
words and behaviours, and the measure-
ment of pain relief is extremely difficult.18
We defined a reduction of two points on an
11-point NRS for pain as ‘significant pain
relief’ and considered this two-point change
to be sufficiently large to be accepted as
clinically significant, that is, to have a
meaningful effect on a patient’s daily life.
Interestingly, a study by Kelly (1998) on
visual analogue scales (VAS) for pain
found that a 9-mm difference on a
100-mm VAS scale was clinically signifi-
cant. This difference would correspond to
a one-point change on the 11-point scale
used in our study,19 and would have
meant that more patients would have
reached the study endpoint. Following the
study, we performed a number of addition-
al analyses to assess efficacy differences
between ibuprofen/levomenthol gel and
ibuprofen gel. If significant pain relief had
been defined as a one-point reduction in
pain score then at 30 minutes, 95% of
patients who received ibuprofen/levomen-
thol gel reported significant pain relief com-
pared with 82% of patients in the ibuprofen
gel group, and this difference would have
been statistically significant (p¼ 0.023).
Other studies have also found that rela-
tively small changes in pain scores can be
clinically significant. Kendrick and Strout
(2005) found that a change of 1.39 (1.05)
was clinically significant when measuring
pain in a study of 354 emergency depart-
ment subjects who were asked to rate
their pain on an 11-point NRS every
20 minutes.14 In addition, Myles et al.
(2017)20 studied an unselected cohort of
patients recovering from surgery and
found that analgesic interventions that pro-
duce a change of 10mm on a 100mm VAS
signify a clinically important change in a
patient’s pain status.
However, clinically significant changes in
pain scores may vary considerably among
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studies. Olsen et al. (2017)21 reviewed 37
studies on acute pain and found that
among 29 suitable studies that used a
mean change approach, absolute minimal
clinically important differences in pain
scores ranged from 8 to 40mm with a
median of 17mm on a standardised
100-mm scale. Clearly, a given treatment
could have a statistically significant effect
that is not clinically significant.
Clinical efficacy may also be measured
by calculating NNT values. In two studies
that used outcomes of marked improve-
ment or complete remission, ibuprofen gel
had an NNT value of 3.9 for treating acute
musculoskeletal pain in adults.1 In a similar
patient population, the EmulgelVR formula-
tion of diclofenac had an NNT value of 1.8
in two studies that used at least 50% pain
intensity reduction as the outcome.1 Using
the outcome of moderate pain relief or
better on our 7-point global pain relief
scale, we found that the ibuprofen/levomen-
thol and diclofenac gels both had the same
NNT value (1.79), whereas the NNT value
for ibuprofen gel was slightly higher (2.18;
Table 4). Interestingly, analysis of our 11-
point NRS pain data using the outcome of
at least 50% pain intensity reduction also
produced a slightly higher value for ibupro-
fen gel (NNT¼ 2.10) than for diclofenac
(NNT¼ 1.65) and ibuprofen/levomenthol
(NNT¼ 1.44) gels.
In addition to investigating the time to
pain relief as a 2-point drop in pain score
from baseline, we evaluated the level of
global pain relief reported by patients at
the end of the 2-hour assessment period
using a 7-point scale. We found no differ-
ence in median global pain relief between
ibuprofen/levomenthol gel and diclofenac
gel, but treatment with either of these gels
resulted in a 1-point superior outcome com-
pared with treatment with ibuprofen gel.
Because this statistically significant differ-
ence was observed on a 7-point scale and
not the 11-point NRS used in the other
analyses, it is more likely to be clinical-
ly important.
A strength of our study was that only
participants with high baseline pain levels
were included, thus ensuring that effective
treatment would cause a larger change in
pain intensity than less effective treat-
ment.13 In addition, conducting the 2-hour
assessment at the clinic meant that patients
could be monitored throughout and
increased the likelihood that pain scores
were entered accurately at the correct time
points, compared with asking patients to
complete a home-based treatment diary.
This study had some limitations, howev-
er. Although we used a power calculation to
determine the number of patients to recruit,
this calculation reflected our definition of
significant pain relief for the primary out-
come (a reduction of two points on an 11-
point NRS). As noted in the results section,
a larger patient population might have
allowed statistically significant differences
in pain relief to be identified when levomen-
thol is added to an ibuprofen gel. In
addition, as discussed above, clinically sig-
nificant changes in pain scores may vary
considerably among studies. Consequently,
we cannot be certain that the changes
reported in our study are clinical-
ly meaningful.
A recent study demonstrated that both a
gel containing levomenthol and a placebo
gel with no levomenthol could decrease
skin temperature and intramuscular tem-
perature in the quadriceps of the anterior
thigh. The gel containing levomenthol
increased cutaneous blood flow, whereas
the placebo gel did not. The gel containing
levomenthol was also subjectively reported
to be cooler.22 In the present study, the
effect of adding levomenthol to a pain
relief gel could be isolated. The only sub-
stantive difference in composition between
the ibuprofen/levomenthol gel and ibupro-
fen gel used in our study was the presence of
levomenthol in the ibuprofen/levomenthol
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gel. The 3% w/w levomenthol in the ibu-
profen/levomenthol gel was replaced by
3% w/w purified water in the ibuprofen
gel. Therefore, differences in efficacy
between these two gels appear to be associ-
ated with levomenthol and cannot be attrib-
uted to gel alcohol content. At the end of
the 2-hour assessment period, significantly
more patients in the ibuprofen/levomenthol
gel treatment group reported cooling
(45.8%) compared with the diclofenac
(16.4%) and ibuprofen (14.7%) gel groups.
At this 2-hour time point, there was a signif-
icant association between reported cooling
and treatment group (p< 0.001).
With respect to the evaluation of temper-
ature perception, it is important to note
that the study design prevented patients
from reporting warming and cooling sensa-
tions at the same time point. The main
reason for this was that the earlier time
points in the study were at shorter intervals,
and it was critical that patients had suffi-
cient time to answer all required questions.
Patients were first asked whether they expe-
rienced warming, and those who answered
“yes” were not asked whether they experi-
enced cooling at that particular time point.
That is, we assumed that patients who expe-
rienced warming would not have experi-
enced cooling simultaneously.
We also performed supplementary statis-
tical analyses to evaluate different but relat-
ed analgesic parameters. However, the
relatively small size of the study population
made it difficult to demonstrate differences
in analgesic performance among the gels at
the 5% CI.
Our study compares favourably with
similar recent investigations that have
used NRSs to assess pain changes.
Bussin et al. (2017) performed a pilot
study in 19 adults with chronic Achilles ten-
dinopathy to evaluate successive treatment
with either 10% diclofenac or placebo gel
over a 3-day period. The primary outcome
measure was pain level on an 11-point NRS
during hopping, which was reduced on
average from 4.8/10 to 3.1/10 by diclofe-
nac.23 The use of chronic conditions to
assess the effectiveness of topical pain
relief gels facilitates the use of a more rig-
orous crossover study design, although it
can be more difficult to demonstrate a clin-
ically significant improvement in pain
scores. Lai et al. (2017)2 used four-times-
daily treatment with 1% diclofenac/3%
menthol gel in adolescents and adults with
acute ankle sprain. They measured the area
under the curve of pain intensity on move-
ment from 24 to 72 hours post-application
using an 11-point NRS for pain and found
no significant improvement compared with
placebo, 1% diclofenac, or 3% menthol gel.
However, other studies have demonstrated
the efficacy of diclofenac gel in treating
acute ankle sprains.24,25
Our study demonstrated that all three
gels had a median time to significant pain
relief of less than 30 minutes. Additionally,
the ibuprofen/levomenthol gel was able to
provide prolonged cooling for up to 2 hours
after gel application. Clearly, the clinical
implication of faster pain relief is that
patients spend less time in pain, while the
rapid onset of pain relief is very important
to patients.26 Cold treatment, typically ice,
is frequently used as an immediate treat-
ment for acute musculoskeletal injuries.
The application of ice has been linked to
reductions in tissue metabolism, haema-
toma formation, inflammation, and tissue
necrosis. In addition, treatment with ice is
associated with analgesia and may acceler-
ate the regeneration of muscle tissues.27–31
Further studies are required to determine
the precise clinical benefits of cooling in the
treatment of acute musculoskeletal injuries.
In addition, any overlap in the mechanistic
pathways by which ice and menthol pro-
duce cold sensations must be investigated
in detail to understand whether benefits
conferred by cold temperature can also be
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gained by using analgesic gels contain-
ing menthol.
Conclusions
The addition of levomenthol to ibuprofen
gel was associated with improved analgesic
performance when compared with a gel
containing only ibuprofen. While all three
gels were associated with effective pain
relief, our results indicate that ibuprofen/
levomenthol gel and diclofenac gel had a
shorter median time to significant pain
relief compared with ibuprofen gel,
although statistically significant differences
were not demonstrated. Based on median
global pain relief 2 hours after application,
ibuprofen gel containing levomenthol pro-
duced pain relief that was superior to that
of standard ibuprofen gel and similar to
that of diclofenac gel. Only ibuprofen/levo-
menthol gel provided prolonged cooling for
up to 2 hours after gel application. No seri-
ous adverse events related to study medica-
tion were recorded in any patients, and no
adverse events related to study medication
were recorded in any patients treated with
either ibuprofen/levomenthol gel or ibupro-
fen gel.
Acknowledgements
The authors wish to thank Bobby Brown and
Clare Douglas who provided medical writ-
ing assistance.
Declaration of conflicting interest
CB is an employee of The Mentholatum
Company Ltd.
Funding
This work was supported by The Mentholatum
Company Ltd.
ORCID iD
Stephen Corson https://orcid.org/0000-0002-
4394-551X
References
1. Derry S, Moore RA, Gaskell H, et al.
Topical NSAIDs for acute musculoskeletal
pain in adults. Cochrane Database Syst Rev
2015; 6: CD007402. doi: 10.1002/14651858.
CD007402.pub3.
2. Lai PM, Collaku A and Reed K. Efficacy
and safety of topical diclofenac/menthol gel
for ankle sprain: a randomized, double-
blind, placebo- and active-controlled trial.
J Int Med Res 2017; 45: 647–661. doi:
10.1177/0300060517700322.
3. The British Medical Association New Guide
to Medicines and Drugs. 9th ed. Dorling
Kindersley, 2015.
4. McPherson ML and Cimino NM. Topical
NSAID formulations. Pain Med 2013; 14:
S35–S39. doi: 10.1111/pme.12288.
5. Gan TJ. Diclofenac: an update on its mech-
anism of action and safety profile. Curr Med
Res Opin 2010; 26: 1715–1731. doi: 10.1185/
03007995.2010.486301.
6. Remington JP and Gennaro AR. Remington’s
pharmaceutical sciences. 18th ed. Easton, PA:
Mack Printing Company, 1990, pp. 765.
7. Hensel H and Zotterman Y. The effect of
menthol on the thermoreceptors. Acta
Physiol Scand 1951; 24: 27–34. doi:
10.1111/j.1748-1716.1951.tb00824.x.
8. Caterina MJ. Transient receptor potential
ion channels as participants in thermosensa-
tion and thermoregulation. Am J Physiol
Regul Integr Comp Physiol 2007; 292:
R64–R76. doi: 10.1152/ajpregu.00446.2006.
9. Sweetman SC. Martindale: the complete
drug reference. 36th ed. London, UK:
Pharmaceutical Press, 2009, pp. 2340.
10. Galeotti N, Di Cesare Mannelli L, Mazzanti
G, et al. Menthol: a natural analgesic com-
pound. Neurosci Lett 2002; 322: 145–148.
11. Medicines.org.uk. Voltarol Pain-eze Emulgel -
Summary of Product Characteristics (SPC) -
(eMC). [online] Available at: https://www.med
icines.org.uk/emc/product/6329 [Accessed 22
Feb. 2018].
12. Altman R and Barkin RL. Topical
therapy for osteoarthritis: clinical and
pharmacologic perspectives. Postgrad
Med 2009; 121: 139–147. doi: 10.3810/
pgm.2009.03.1986.
14 Journal of International Medical Research 0(0)
13. Breivik H, Borchgrevink PC, Allen SM,
et al. Assessment of pain. Br J Anaesth
2008; 101: 17–24. doi: 10.1093/bja/aen103.
Epub 2008 May 16.
14. Kendrick DB and Strout TD. The minimum
clinically significant difference in patient-
assigned numeric scores for pain. Am J
Emerg Med 2005; 23: 828–832. doi:
10.1016/j.ajem.2005.07.009.
15. Lehmann EL. Nonparametrics: statistical
methods based on ranks. 2nd ed. NJ, USA:
Prentice Hall, 1998, pp. 76–81.
16. Hjermstad MJ, Fayers PM, Haugen DF,
et al. Studies comparing numerical rating
scales, verbal rating scales, and visual ana-
logue scales for assessment of pain intensity
in adults: a systematic literature review.
J Pain Symptom Manage 2011; 41: 1073–1093.
doi: 10.1016/j.jpainsymman.2010.08.016.
17. Medicines and Healthcare products Regulatory
Agency. The Blue Guide: Advertising and
Promotion of Medicines in the UK. 3rd ed. –
1st revision, September 2014.
18. Simons DG, Travell JG and Simons LS.
Travell & Simons’ myofascial pain and dys-
function: the trigger point manual. 2nd ed.
MD, USA: Lippincott Williams & Wilkins,
1999, pp. 268–269.
19. Kelly AM. Does the clinically significant dif-
ference in visual analog scale pain scores
vary with gender, age, or cause of pain?
Acad Emerg Med 1998; 5: 1086–1090. doi:
https://doi.org/10.1111/j.1553-2712.1998.
tb02667.x.
20. Myles PS, Myles DB, Galagher W, et al.
Measuring acute postoperative pain using
the visual analog scale: the minimal clinically
important difference and patient acceptable
symptom state. Br J Anaesth 2017; 118:
424–429. doi: 10.1093/bja/aew466.
21. Olsen MF, Bjerre E, Hansen MD, et al. Pain
relief that matters to patients: systematic
review of empirical studies assessing the
minimum clinically important difference in
acute pain. BMC Med 2017; 15: 35. doi:
10.1186/s12916-016-0775-3.
22. Hunter AM, Grigson C and Wade A.
Influence of topically applied menthol cool-
ing gel on soft tissue thermodynamics and
arterial and cutaneous blood flow at rest.
Int J Sports Phys Ther 2018; 13: 483–492.
doi: 10.26603/ijspt20180483.
23. Bussin ER, Cairns B, Bovard J, et al.
Randomised controlled trial evaluating the
short-term analgesic effect of topical diclofe-
nac on chronic Achilles tendon pain: a pilot
study. BMJ Open 2017; 7: e015126. doi:
10.1136/bmjopen-2016-015126.
24. ClinicalTrials.gov. Efficacy and safety of diclo-
fenac sodium topical gel 1% applied four times
daily in subjects with acute ankle sprain
(NCT01272934). [online] Available at: https://
clinicaltrials.gov/ct2/show/NCT01272934
[Accessed April 24, 2018].
25. Predel HG, Hamelsky S, Gold M, et al.
Efficacy and safety of diclofenac diethyl-
amine 2.32% gel in acute ankle sprain.
Med Sci Sport Exer 2012; 44: 1629–1636.
doi: 10.1249/MSS.0b013e318257ed41.
26. Kluger MT and Owen H. Patients’ expect-
ations of patient-controlled analgesia.
Anaesthesia 1990; 45: 1072–1074. doi:
https://doi.org/10.1111/j.1365-2044.1990.
tb14893.x.
27. J€arvinen TA, J€arvinen TL, K€a€ari€ainen M,
et al. Muscle injuries: biology and treatment.
Am J Sports Med 2005; 33: 745–764. doi:
https://doi.org/10.1177/0363546505274714
28. J€arvinen TA, J€arvinen TL, K€a€ari€ainen M,
et al. Muscle injuries: optimising recovery.
Best Pract Res Clin Rheumatol 2007; 21:
317–331. doi: https://doi.org/10.1016/j.berh.
2006.12.004.
29. Bleakley C, McDonough S and MacAuley
D. The use of ice in the treatment of
acute soft-tissue injury. Am J Sports Med
2004; 32: 251–261. doi: https://doi.org/10.
1177/0363546503260757.
30. Bleakley CM, O’Connor S, Tully MA, et al.
The PRICE study (Protection Rest Ice
Compression Elevation): design of a rando-
mised controlled trial comparing standard
versus cryokinetic ice applications in the
management of acute ankle sprain
[ISRCTN13903946]. BMC Musculoskelet
Disord 2007; 8: 125–132. doi: 10.1186/1471-
2474-8-125.
31. Brukner P and Khan K. Brukner & Khan’s
clinical sports medicine. 4th ed. Sydney:
McGraw-Hill, 2012, pp. 165–166.
Wade et al. 15
